IS ANKTIVA RIGHT FOR YOU?
Go ahead and TRI.
Anktiva is an Immunotherapy that Activates Your Body’s Cancer Fighting Cells
Anktiva is the first U.S. FDA-approved immunotherapy that activates a type of cell called a natural killer (NK) cell, part of the body’s natural immune system, to attack and kill non-muscle invasive bladder cancer (NMIBC) cells.1 Anktiva is a treatment for use in combination with a standard treatment for NMIBC, bacillus Calmette-Guérin (BCG), for people with NMIBC for whom BCG alone was not effective or in whom NMIBC returned after initial successful treatment. These people have what is termed BCG-unresponsive NMIBC.
QUILT-3.032 Study
of study participants achieved a complete response, meaning their cancer was eliminated
(n=77; 95% CI: 51-73).1
Biopsy confirmed.
58% (n=28) ≥12 months; 40% (n=19) ≥24 months; range: 0.0–47.0+ months.1
+ Denotes an ongoing response.
Full Enrollment Follow-up
of study participants had a complete response
(n=100; 95% CI: 61.1-79.6).2
Biopsy confirmed.
Some patients remained NMIBC-free for over 4 years.2
+ Denotes an ongoing response.
QUILT-3.032 is a multicenter, single-arm study in adults with BCG-unresponsive high-risk NMIBC with CIS ± Ta/T1 papillary disease. Efficacy was evaluated in 77 adults (label), with updated follow-up in 100 patients. Patients received nogapendekin alfa inbakicept-pmln 400 mcg plus BCG weekly for 6 weeks, with re-induction permitted at month 3. The primary endpoint was complete response.1,2
References: 1. Anktiva (nogapendekin alfa inbakicept-pmln) prescribing information. ImmunityBio, 2024. 2. Chang, S. (2025, April 26-29). An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.
Who Should Consider Anktiva?
Anktiva is a treatment for adults who have all the following:
- High-risk non-muscle invasive bladder cancer
- NMIBC that did not or is no longer responding to BCG therapy alone (BCG-unresponsive)
- NMIBC that has not grown beyond the inner lining of the bladder to the muscle underneath (called carcinoma in situ or CIS disease)
- NMIBC with or without small finger-like tumor growths that project away from the bladder wall into the bladder (papillary disease)
If You Have Been Diagnosed With BCG-Unresponsive NMIBC With CIS Disease and Are Interested in Anktiva, Here Is What You Need to Know:
What Anktiva is
- Anktiva is an immunotherapy that activates your body’s natural immune system
- Anktiva is used in combination with BCG and is administered directly into your bladder via a catheter intravesically
- Anktiva is the first treatment of its type approved to treat BCG-unresponsive NMIBC with CIS
What Anktiva is not
- Anktiva is not a chemotherapy
- Anktiva is not administered via IV. It only fights cancer in the bladder
- Anktiva is not an indirect mechanism, it directly stimulates the immune response
Getting Started With Anktiva
A patient-friendly overview of how Anktiva plus BCG work together, as well as what patients should expect before and after treatment
Patient Stories
Patients Like You
Read about patients who participated in the clinical trials for Anktiva
Justin’s Journey
An avid outdoorsman, Justin faced a challenging diagnosis of non-muscle invasive bladder cancer. After struggling with the side effects of his Bacillus Calmette-Guérin (BCG) treatment, he found renewed hope though his doctors' introduction to an immunotherapy for those who experienced a recurrence of NMIBC.
Wayne’s Journey
Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who “just likes people.” When he was first told, “you might have a tumor in your bladder,” he became very concerned, especially when he learned his first treatment with BCG wasn’t working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.
When BCG Alone Isn’t Enough,
Bring On the Tri-Offense With Anktiva.
For more information, please call 1-877-ANKTIVA.
